Literature DB >> 33674403

Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma.

Gerben J C Zwezerijnen1, Jakoba J Eertink2, Coreline N Burggraaff2, Sanne E Wiegers2, Ekhlas A I N Shaban3, Simone Pieplenbosch1, Daniela E Oprea-Lager1, Pieternella J Lugtenburg4, Otto S Hoekstra1, Henrica C W de Vet5, Josee M Zijlstra2, Ronald Boellaard6.   

Abstract

Metabolic tumor volume (MTV) on interim PET (I-PET) is a potential prognostic biomarker for diffuse large B-cell lymphoma (DLBCL). Implementation of MTV on I-PET requires a consensus on which semiautomated segmentation method delineates lesions most successfully with least user interaction. Methods used for baseline PET are not necessarily optimal for I-PET because of lower lesional SUVs at I-PET. Therefore, we aimed to evaluate which method provides the best delineation quality for Deauville score (DS) 4-5 DLBCL lesions on I-PET at the best interobserver agreement on delineation quality and, second, to assess the effect of lesional SUVmax on delineation quality and performance agreement.
Methods: DS 4-5 lesions from 45 I-PET scans were delineated using 6 semiautomated methods: a fixed SUV threshold of 2.5 g/cm3, a fixed SUV threshold of 4.0 g/cm3, an adaptive threshold corrected for source-to-local background activity contrast at 50% of the SUVpeak, 41% of SUVmax per lesion, a majority vote including voxels detected by at least 2 methods, and a majority vote including voxels detected by at least 3 methods (MV3). Delineation quality per MTV was rated by 3 independent observers as acceptable or nonacceptable. For each method, observer scores on delineation quality, specific agreement, and MTV were assessed for all lesions and per category of lesional SUVmax (<5, 5-10, >10).
Results: In 60 DS 4-5 lesions on I-PET, MV3 performed best, with acceptable delineation in 90% of lesions and a positive agreement of 93%. Delineation quality scores and agreement per method strongly depended on lesional SUV: the best delineation quality scores were obtained using MV3 in lesions with an SUVmax of less than 10 and using SUV4.0 in more 18F-FDG-avid lesions. Consequently, overall delineation quality and positive agreement improved by applying the most preferred method per SUV category instead of using MV3 as the single best method. The MV3- and SUV4.0-derived MTVs of lesions with an SUVmax of more than 10 were comparable after exclusion of visually failed MV3 contouring. For lesions with an SUVmax of less than 10, MTVs using different methods correlated poorly.
Conclusion: On I-PET, MV3 performed best and provided the highest interobserver agreement regarding acceptable delineations of DS 4-5 DLBCL lesions. However, delineation-method preference strongly depended on lesional SUV. Therefore, we suggest exploration of an approach that identifies the optimal delineation method per lesion as a function of tumor 18F-FDG uptake characteristics, that is, SUVmax.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  PET; lymphoma; metabolic tumor volume; stand-ardization

Mesh:

Substances:

Year:  2021        PMID: 33674403      PMCID: PMC8612315          DOI: 10.2967/jnumed.120.258673

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  37 in total

1.  Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.

Authors:  Virginie Frings; Adrianus J de Langen; Egbert F Smit; Floris H P van Velden; Otto S Hoekstra; Harm van Tinteren; Ronald Boellaard
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

2.  ATLAAS: an automatic decision tree-based learning algorithm for advanced image segmentation in positron emission tomography.

Authors:  Beatrice Berthon; Christopher Marshall; Mererid Evans; Emiliano Spezi
Journal:  Phys Med Biol       Date:  2016-06-08       Impact factor: 3.609

3.  Clinicians are right not to like Cohen's κ.

Authors:  Henrica C W de Vet; Lidwine B Mokkink; Caroline B Terwee; Otto S Hoekstra; Dirk L Knol
Journal:  BMJ       Date:  2013-04-12

4.  Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study.

Authors:  Virginie Frings; Floris H P van Velden; Linda M Velasquez; Wendy Hayes; Peter M van de Ven; Otto S Hoekstra; Ronald Boellaard
Journal:  Radiology       Date:  2014-05-26       Impact factor: 11.105

5.  Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).

Authors:  Pieternella Johanna Lugtenburg; Peter de Nully Brown; Bronno van der Holt; Francesco A D'Amore; Harry R Koene; Eva de Jongh; Rob Fijnheer; Joost W van Esser; Lara H Böhmer; Johannes F Pruijt; Gregor E Verhoef; Mels Hoogendoorn; Memis Y Bilgin; Marcel Nijland; Nicole C van der Burg-de Graauw; Margreet Oosterveld; Kon-Siong G Jie; Thomas Stauffer Larsen; Marjolein W van der Poel; Maria B Leijs; Matthijs H Silbermann; Marinus van Marwijk Kooy; Aart Beeker; Marie J Kersten; Jeanette K Doorduijn; Lidwine W Tick; Rolf E Brouwer; King H Lam; Coreline N Burggraaff; Bart de Keizer; Anne I Arens; Daphne de Jong; Otto S Hoekstra; Josée M Zijlstra-Baalbergen
Journal:  J Clin Oncol       Date:  2020-07-30       Impact factor: 44.544

6.  Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma.

Authors:  Xingchen Wu; Hannu Pertovaara; Pasi Korkola; Martine Vornanen; Ritva Järvenpää; Prasun Dastidar; Hannu Eskola; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Acta Oncol       Date:  2014-06-24       Impact factor: 4.089

7.  Combined Visual and Semiquantitative Evaluation Improves Outcome Prediction by Early Midtreatment 18F-FDG PET in Diffuse Large B-Cell Lymphoma.

Authors:  Tamás Györke; Robert Carr; Juliano J Cerci; Claudio Meneghetti; Francisca Redondo; Monica Celli; Charity Gorospe; Chirayu U Auewarakul; Linda Jorgov; Diana Paez; Stefano Fanti
Journal:  J Nucl Med       Date:  2019-11-22       Impact factor: 10.057

8.  Comparison of 11 automated PET segmentation methods in lymphoma.

Authors:  Amy J Weisman; Minnie W Kieler; Scott Perlman; Martin Hutchings; Robert Jeraj; Lale Kostakoglu; Tyler J Bradshaw
Journal:  Phys Med Biol       Date:  2020-11-27       Impact factor: 3.609

9.  Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma.

Authors:  Luis F Oñate-Ocaña; Violeta Cortés; Rodrigo Castillo-Llanos; Andrea Terrazas; Osvaldo Garcia-Perez; Quetzalli Pitalúa-Cortes; Mayra Ponce; Alfonso Dueñas-Gonzalez; Myrna Candelaria
Journal:  Oncol Lett       Date:  2018-05-25       Impact factor: 2.967

10.  PET segmentation of bulky tumors: Strategies and workflows to improve inter-observer variability.

Authors:  Elisabeth Pfaehler; Coreline Burggraaff; Gem Kramer; Josée Zijlstra; Otto S Hoekstra; Mathilde Jalving; Walter Noordzij; Adrienne H Brouwers; Marc G Stevenson; Johan de Jong; Ronald Boellaard
Journal:  PLoS One       Date:  2020-03-30       Impact factor: 3.240

View more
  1 in total

1.  Combatting the effect of image reconstruction settings on lymphoma [18F]FDG PET metabolic tumor volume assessment using various segmentation methods.

Authors:  Maria C Ferrández; Jakoba J Eertink; Sandeep S V Golla; Sanne E Wiegers; Gerben J C Zwezerijnen; Simone Pieplenbosch; Josée M Zijlstra; Ronald Boellaard
Journal:  EJNMMI Res       Date:  2022-07-29       Impact factor: 3.434

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.